Previous 10 | Next 10 |
HOUSTON, May 16, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) , a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that it has closed i...
2023-05-12 08:13:53 ET Salarius Pharmaceuticals ( NASDAQ: SLRX ) has entered into definitive agreements for the issuance and sale of an aggregate of 3.64M shares of its common stock, Series A-1, A-2 warrants of ~3.64 shares respectively, at a purchase price of $1.65/share...
HOUSTON, May 12, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that it has entered into ...
2023-05-11 09:08:27 ET Salarius Pharmaceuticals press release ( NASDAQ: SLRX ): Q1 GAAP EPS of -$2.23 beats by $0.31 . Cash and cash equivalents were $9.3 million as of March 31, 2023, compared with $12.1 million as of December 31, 2022. Current cash and cash equiv...
FDA removes partial clinical hold on seclidemstat Phase 1/2 trial in Ewing sarcoma; Salarius plans to meet with FDA to discuss future development and potential registration pathways SP-3164 targeted protein degrader preclinical data presented at AACR 2023 shows compelling anticancer act...
2023-05-09 09:07:41 ET Salarius Pharma ( NASDAQ: SLRX ) announced that the US Food and Drug Administration (FDA) has lifted the partial clinical hold on its Phase 1/2 Ewing sarcoma clinical trial, which is evaluating the efficacy of seclidemstat. Seclidemstat, Salarius Pharma'...
Decision Follows Review of Comprehensive Safety Data Package Submitted by the Company Salarius Plans to Meet with FDA to Discuss Future Development and Potential Registration Pathways HOUSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) ...
2023-05-01 12:00:00 ET Salarius Pharma ( NASDAQ: SLRX ) completes 2 Good Laboratory Practice toxicology studies on its protein degrader SP-3164, with no unexpected safety findings. The company said the GLP toxicology reports will be included in the investigational new drug app...
HOUSTON, May 01, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) , a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, announces the completion of two Good...
SP-3164 demonstrates compelling antitumor activity in animal models of follicular lymphoma and compelling antitumor activity in animal models of multiple myeloma Preclinical findings support the Company’s planned clinical development of SP-3164 in hematologic cancers HOUSTON, April...
News, Short Squeeze, Breakout and More Instantly...
Salarius Pharmaceuticals Inc. Company Name:
SLRX Stock Symbol:
NYSE Market:
Salarius Pharmaceuticals Inc. Website:
2024-06-17 09:02:04 ET Solar Acquisition Corp (SLRX) announced stock split at a ratio of 1-for-8 on 2024-06-17 ... Full story available on KlickAnalytics.com
Patients were treated in the dose-escalation portion of the Phase 1/2 study evaluating seclidemstat in combination with azacitidine Investigators reported a 43% overall response rate among 14 predominantly higher risk myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (C...
HOUSTON, June 12, 2024 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) , a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that it will effect...